172733-79-8

Basic information

• Product Name: Spiro[isobenzofuran-1(3H),4'-piperidin]-3-one hydrochloride
• Synonyms: Spiro[isobenzofuran-1(3H),4'-piperidin]-3-one hydrochloride;3H-spiro[isobenzofuran-1,4'-piperidin]-3-one hydrochloride;3-Oxo-1,3-dihydrospiro[isobenzofuran-1,4'-piperidine] Hydrochloride
• CAS NO: 172733-79-8
• Molecular Formula: C12H14ClNO2
• Molecular Weight: 239.7
• Mol File: 172733-79-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Spiro[isobenzofuran-1(3H),4'-piperidin]-3-one hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Spiro[isobenzofuran-1(3H),4'-piperidin]-3-one hydrochloride(172733-79-8)
• EPA Substance Registry System: Spiro[isobenzofuran-1(3H),4'-piperidin]-3-one hydrochloride(172733-79-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 172733-79-8(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 172733-79-8 differently. You can refer to the following data:
1. Spiro[isobenzofuran-1(3H),4'-piperidin]-3-one is a (spiro)(hetero)cyclic amides as modulator of 11-β hydroxysteroid dehydrogenase type 1.
2. Spiro[isobenzofuran-1(3H),4''-piperidin]-3-one is a (spiro)(hetero)cyclic amides as modulator of 11-β hydroxysteroid dehydrogenase type 1.

Upstream product

• 54596-01-9 1'-benzylspiro[isobenzofuran-1(3H),4'-piperidin]-3-one hydrochloride 
• 37663-42-6 1'-benzylspiro[isobenzofuran-1(3H),4'-piperidine]-3-one 

Relevant articles and documents

Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole derivatives

Design, syntheses, and structure-activity relationships of a novel class of 2-{3-oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole NPY Y5 receptor antagonists are described. The benzimidazole structures were newly designed based on the urea linkage of our prototype Y5 receptor antagonists (2 and 3). By optimizing substituents on the benzimidazole core part of the lead compound 5a, we were able to develop a potent, orally available, and brain-penetrable Y5 selective antagonist (5k). Crown Copyright

MODULATORS OF MUSCARINIC RECEPTORS

The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.